Goldman Sachs’s Rapid Micro Biosystems RPID Stock Holding History

Goldman Sachs’s Portfolio RPID Stock Details RPID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$163K	Buy	71,912 +16,606	+30%	+$60.8K	﹤0.01%	6133
2025 Q4	$160K	Buy	+55,306	New	+$192K	﹤0.01%	6095
2024 Q2	–	Sell	-18,639	Closed	-$18.1K	–	5880
2024 Q1	$18.1K	Sell	18,639 -199,648	-91%	-$194K	﹤0.01%	5400
2023 Q4	$162K	Sell	218,287 -729,494	-77%	-$747K	﹤0.01%	5208
2023 Q3	$1.02M	Buy	947,781 +6,424	+0.7%	+$6.38K	﹤0.01%	4257
2023 Q2	$941K	Sell	941,357 -2,983	-0.3%	-$3.02K	﹤0.01%	4378
2023 Q1	$1.24M	Sell	944,340 -89,001	-9%	-$116K	﹤0.01%	4227
2022 Q4	$1.17M	Buy	1,033,341 +1,003,400	+3,351%	+$2.43M	﹤0.01%	4327
2022 Q3	$97K	Sell	29,941 -23,549	-44%	-$91.4K	﹤0.01%	5689
2022 Q2	$230K	Buy	53,490 +22,545	+73%	+$105K	﹤0.01%	5575
2022 Q1	$210K	Sell	30,945 -126,970	-80%	-$935K	﹤0.01%	5856
2021 Q4	$1.68M	Buy	157,915 +24,402	+18%	+$381K	﹤0.01%	4400
2021 Q3	$2.47M	Buy	+133,513	New	+$2.76M	﹤0.01%	3995

Other funds holding RPID

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

AWGLSCP

ABG-WTT Global Life Science Capital Partners Central, Hong Kong, Hong Kong $12.3M AUM 3.13% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

EFA

Evernest Financial Advisors Carmel, Indiana $481M AUM 19.97% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LCM

Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's RPID Position: Q1 2026 in Review

Goldman Sachs increased its Rapid Micro Biosystems (RPID) stake by 30% in Q1 2026, buying an estimated $60.8K and bringing the position to 71,912 shares worth $163K. The position accounts for ﹤0.01% of the portfolio, ranked #6133.

Goldman Sachs first reported a position in RPID in Q3 2021 and has held it in 13 quarters since. The position peaked at $2.47M in Q3 2021. 46 funds tracked by Wall St. Rank hold RPID as of Q1 2026.

Goldman Sachs held 71,912 shares of Rapid Micro Biosystems worth $163K as of Q1 2026.
Goldman Sachs bought 16,606 Rapid Micro Biosystems shares in Q1 2026, an estimated $60.8K.
Rapid Micro Biosystems made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6133 holding.
Goldman Sachs first reported a position in Rapid Micro Biosystems in Q3 2021 and has held it in 13 quarters since.
Goldman Sachs's Rapid Micro Biosystems position peaked at $2.47M in Q3 2021.
46 funds tracked by Wall St. Rank held Rapid Micro Biosystems as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.